Sudershan Bhatia

Learn More
Cancer cells, relative to normal cells, demonstrate significant alterations in metabolism that are proposed to result in increased steady-state levels of mitochondrial-derived reactive oxygen species (ROS) such as O2(•-)and H2O2. It has also been proposed that cancer cells increase glucose and hydroperoxide metabolism to compensate for increased levels of(More)
PURPOSE To quantify the dosimetric impact of applicator displacements and applicator reconstruction-uncertainties through simulated planning studies of virtual applicator shifts. MATERIAL AND METHODS Twenty randomly selected high-dose-rate (HDR) titanium tandem-and-ovoid (T&O) plans were retrospectively studied. MRI-guided, conformal brachytherapy(More)
PURPOSE To evaluate conventional brachytherapy (BT) plans using dose-volume parameters and high resolution (3 Tesla) MRI datasets, and to quantify dosimetric benefits and limitations when MRI-guided, conformal BT (MRIG-CBT) plans are generated. MATERIAL AND METHODS Fifty-five clinical high-dose-rate BT plans from 14 cervical cancer patients were(More)
In this paper, we propose a novel method to reduce the magnitude of 4D CT artifacts by stitching two images with a data-driven regularization constrain, which helps preserve the local anatomy structures. Our method first computes an interface seam for the stitching in the overlapping region of the first image, which passes through the "smoothest" region, to(More)
PURPOSE We perform a clinical retrospective study to determine whether a vaginal balloon-packing system provides a dosimetric reduction to organs at risk (OARs) versus traditional gauze packing for gynecological high-dose-rate brachytherapy (HDR-BT). We also test various balloon filling materials for optimizing imaging quality. MATERIAL AND METHODS(More)
OBJECTIVE Evaluate the impact of radiotherapy on cause specific survival (CSS) and overall survival (OS) for stage (I-III) clear cell, mucinous, and endometriod ovarian cancer. METHODS We analyzed incidence, survival, and treatments from the Surveillance, Epidemiology, and End Results (SEER) Program from 2004 to 2011 for clear cell, mucinous, and(More)
  • 1